Amoytop Biotech released its 2026 interim report. Operating revenue was 1.84 billion yuan, up 21.6% year on year. Net profit attributable to the parent was 477 million yuan, up 11.4% year on year. Net profit attributable to the parent after deducting non-recurring items was 488 million yuan, up 13.2% year on year. Second-quarter operating revenue was 1.04 billion yuan, up 24.1% year on year, and net profit attributable to the parent was 312 million yuan, up 27.0% year on year. The company said its approved drug Pegbin has become the world's first drug with clinical cure as the treatment goal, making significant progress in the treatment of chronic hepatitis B. The launch of its growth hormone product Yipaisheng and its inclusion in medical insurance have also brought new revenue growth points.
Xiamen Amoytop Biotech Co LtdFirst-half net profit up 11.4% and revenue up 21.6%, with strong Q2 growth.
